Authored By: Sarah
14 Jan 2024

Breakthroughs in Acute Ischemic Stroke Therapeutics: A 5.72% CAGR Forecast through 2023- 2027

In the ever-evolving landscape of healthcare, the Acute Ischemic Stroke (AIS) Therapeutics Market is poised for remarkable growth, with an anticipated CAGR of 5.72% between 2023 and 2027. The market advancement will trigger a substantial USD 1,524.49 million in revenue generation across the globe. The rising prevalence of the disease is fueled by the adoption of Novel Oral Anticoagulants (NOACs), and the escalating impact of sedentary lifestyles.

High-Risk Factors Propel AIS Therapeutics Market:

At the forefront of this growth trajectory are high-risk factors such as obesity, atherosclerosis, hypertension, and aging, collectively steering the AIS therapeutics market. As cardiovascular diseases, notably Myocardial Infarction (MI) and stroke, loom as leading global causes of disability and mortality,

AIS emerges as a pivotal focus. Recognized as the most prevalent form of stroke. Swift treatment with alteplase within the critical 3-4 hour window from the onset of stroke symptoms is paramount to prevent disability or even fatality.

Acute Ischemic Stroke Therapy Overview

Acute Ischemic Stroke Therapeutics Market Analysis

Statistical Snapshot:

  • Ischemic stroke accounts for about 87% of all strokes.
  • Stroke ranks as the second-leading cause of death globally.
  • Approximately 15-16 million people suffer from strokes globally, leading to 5.8-6 million deaths.

TBI: Elevating AIS Research to New Heights:

Translational Bioinformatics (TBI) emerges as a pivotal trend in revolutionizing AIS therapeutics. As a complex cardiac disease necessitating an integrated approach, AIS now benefits from the TBI as this modern approach enhances clinical guidelines for AIS treatment and prevention facilitating better treatment approaches.

Key Elements of TBI in AIS:

  • Integration of genotypic data (risk genes) with clinical elements extracted from diagnostic tests.
  • Enhanced data representation through vocabularies like Gene Ontology and SNOMED-CT.

Core Companies and Strategic Advancements:

Prominent players shaping the AIS therapeutics market landscape are actively fortifying their positions. Among these industry players are Athersys Inc., Bayer AG, Biogen Inc., Boehringer Ingelheim International GmbH, Medtronic Plc, NoNO Inc., SanBio Co Ltd., Stryker Corp., Amgen Inc., AstraZeneca Plc, and Bristol Myers Squibb Co. These market influencers are strategically navigating through alliances, partnerships, mergers, acquisitions, geographical expansions, and product/service launches, showcasing their commitment to market dominance.

As the AIS therapeutics market charts an upward trajectory, driven by the confluence of high-risk factors, innovative approaches like TBI, and strategic initiatives by industry giants, the forecasted period promises not just growth but a revolution in AIS treatment paradigms. For a comprehensive understanding of the market dynamics and trends, request a sample report today.

Key data covered in the Acute Ischemic Stroke Therapeutics Market report 

  • Precise market size estimation during the forecast period 2023-2027.  

  • CAGR of the acute ischemic stroke (AIS) therapeutics market forecast during 2023-2027.  

  • Market-level data on units, average selling prices, and values of the acute ischemic stroke (AIS) therapeutics market share.  

  • Prediction of the upcoming trends, drivers, and factors that challenge the growth of the acute ischemic stroke (AIS) therapeutics market.  

  • Acute ischemic stroke (AIS) therapeutics industry growth across North America, Europe, Asia, and Rest of World (ROW).

Read News Read Less
Interested in this report?
Get your sample now!